NCT06484062View on ClinicalTrials.gov

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

PHASE1RecruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

August 15, 2025

Primary Completion Date

June 1, 2028

Study Completion Date

June 1, 2028

Conditions
Acute Myeloid LeukemiaMyelodysplastic SyndromeRecurrent Acute Myeloid LeukemiaRecurrent Myelodysplastic SyndromeRefractory Acute Myeloid LeukemiaRefractory Myelodysplastic Syndrome
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow aspiration

DRUG

Cirtuvivint

Given PO

DRUG

Decitabine and Cedazuridine

Given PO

PROCEDURE

Echocardiography Test

Undergo ECHO

PROCEDURE

Multigated Acquisition Scan

Undergo MUGA

Trial Locations (5)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

21201

RECRUITING

University of Maryland/Greenebaum Cancer Center, Baltimore

30322

RECRUITING

Emory University Hospital/Winship Cancer Institute, Atlanta

60637

RECRUITING

University of Chicago Comprehensive Cancer Center, Chicago

02215

RECRUITING

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH